Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

Erik E Hauzman, Azucena Zapata, Alfonso Bermejo, Carlos Iglesias, Antonio Pellicer, Juan A Garcia-Velasco, Erik E Hauzman, Azucena Zapata, Alfonso Bermejo, Carlos Iglesias, Antonio Pellicer, Juan A Garcia-Velasco

Abstract

Background: Both oral contraceptive pills (OCPs) and estradiol (E2) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E2 valerate.

Methods: Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18-38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts) undergoing IVF with the GnRH antagonist protocol were randomized to either the OCP or E2 pretreatment arms, with no restrictions such as blocking or stratification. Authors involved in data collection and analysis were blinded to group assignment. Fifty patients received OCP (30 μg ethinyl E2/150 μg levonorgestrel) for 12-16 days from day 1 or 2, and stimulation was started 5 days after stopping OCP. Similarly, 50 patients received 4 mg/day oral E2 valerate from day 20 for 5-12 days, until the day before starting stimulation.

Results: Pretreatment with OCP (mean±SD, 14.5±1.7 days) was significantly longer than with E2 (7.8±1.9 days). Stimulation and embryological characteristics were similar. Ongoing pregnancy rates (46.0% vs. 44.0%; risk difference, -2.0% [95% CI -21.2% to 17.3%]), as well as implantation (43.5% vs. 47.4%), clinical pregnancy (50.0% vs. 48.0%), clinical miscarriage (7.1% vs. 7.7%), and live birth (42.0% vs. 40.0%) rates were comparable between groups.

Conclusions: This is the first study to directly compare these two methods of cycle scheduling in GnRH antagonist cycles. Our results fail to show statistically significant differences in ongoing pregnancy rates between pretreatment with OCP and E2 for IVF with the GnRH antagonist protocol. Although the study is limited by its sample size, our results may contribute to a future meta-analysis. An interesting future direction would be to extend our study to women with decreased ovarian reserve, as these are the patients in whom an increase in oocyte yield-due to the hypothetical beneficial effect of steroid pretreatment on follicular synchronization-could more easily be demonstrated.

Trial registration: ClinicalTrials.gov http://NCT01501448.

Figures

Figure 1
Figure 1
CONSORT 2010 flowchart. Note: ITT = intention-to-treat.
Figure 2
Figure 2
Distribution of oocyte retrievals across days of the week with OCP and E2 pretreatment, respectively. Note: Dashed horizontal line at 14.3% (1/7) shows proportion of retrievals per day expected to occur by pure chance.

References

    1. Devroey P, Aboulghar M, Garcia-Velasco J, Griesinger G, Humaidan P, Kolibianakis E, Ledger W, Tomás C, Fauser BC. Improving the patient’s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod. 2009;24:764–774.
    1. Al-Inany HG, Youssef MAFM, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;5 CD001750.
    1. Mortimer D, Mortimer ST. Quality and risk management in the IVF laboratory. Cambridge: Cambridge University Press; 2005.
    1. González RM, Canales E, García R, Martín C, Roldán M, Fernández M, Prados N. Proceedings of the XXIth national congress of AETEL. Madrid: AETEL; 2008. Recuperación real de la temperatura y porcentaje de CO2 en los incubadores de fecundación in vitro.
    1. Janssens R, Souffreau R, Haentjens P, Van de Velde H, Verheyen G. Clinical outcome after culturing human preimplantation embryos in incubators with individual chambers compared to standard incubators; randomised trial [abstract] Hum Reprod. 2011;26:i40–i41.
    1. Frydman R, Forman R, Rainhorn JD, Belaisch-Allart J, Hazout A, Testart J. A new approach to follicular stimulation for in vitro fertilization: programmed oocyte retrieval. Fertil Steril. 1986;46:657–662.
    1. Wardle PG, Foster PA, Mitchell JD, McLaughlin EA, Williams JAC, Corrigan E, Ray BD, McDermott A, Hull MG. Norethisterone treatment to control timing of IVF cycle. Hum Reprod. 1986;1:455–457.
    1. Zorn JR, Boyer P, Guichard A. Never on a Sunday: programming for IVF-ET and GIFT. Lancet. 1987;1(8529):385–386.
    1. Gerli S, Remohí J, Partrizio P, Borrero C, Balmaceda JP, Silber SJ, Asch RH. Programming of ovarian stimulation with norethindrone acetate in IVF/GIFT cycles. Hum Reprod. 1989;4:746–748.
    1. de Ziegler D, Jääskelaïnen AS, Brioschi PA, Fanchin R, Bulletti C. Synchronisation of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH) Hum Reprod. 1998;13:561–564. doi: 10.1093/humrep/13.3.561.
    1. Rombauts L, Healy D, Norman RJ. Comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum Reprod. 2006;13:235–245.
    1. Kolibianakis EM, Papanikolau EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod. 2006;21:352–357.
    1. Griesinger G, Kolibianakis EM, Venetis C, Diedrich K, Tarlatzis B. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril. 2010;94:2382–2384. doi: 10.1016/j.fertnstert.2010.04.025.
    1. Griesinger G, Venetis CA, Marx T, Diedrich K, Tarlatzis BC, Kolibianakis EM. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril. 2008;90:1055–1063. doi: 10.1016/j.fertnstert.2007.07.1354.
    1. Garcia-Velasco JA, Bermejo A, Ruiz F, Martínez Salazar J, Requena A, Pellicer A. Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertil Steril. 2011;96:590–593. doi: 10.1016/j.fertnstert.2011.06.022.
    1. Le Nestour E, Marraoui J, Lahlou N, Roger M, de Ziegler D, Bouchard P. Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal–follicular transition. J Clin Endocrinol Metab. 1993;77:439–442. doi: 10.1210/jc.77.2.439.
    1. Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod. 2003;18:2698–2703. doi: 10.1093/humrep/deg516.
    1. Blockeel C, Engels S, De Vos M, Haentjens P, Polyzos NP, Stoop D, Camus M, Devroey P. Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial. Reprod Biomed Online. 2012;24:272–280. doi: 10.1016/j.rbmo.2011.11.012.
    1. Cédrin-Durnerin I, Guivarc’h-Levêque A, Hugues JN. Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertil Steril. 2012;97:1359–1364. doi: 10.1016/j.fertnstert.2012.02.028.
    1. Ye H, Huang GN, Zeng PH, Pei L. IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long agonist protocol: a prospective and randomized study. J Assist Reprod Genet. 2009;26:105–111. doi: 10.1007/s10815-009-9300-3.
    1. Fanchin R, Schönauer LM, Cunha-Filho JS, Méndez Lozano DH, Frydman R. Coordination of antral follicle growth: basis for innovative concepts of controlled ovarian hyperstimulation. Semin Reprod Med. 2005;23:354–362. doi: 10.1055/s-2005-923393.
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod. 2004;19:41–47.
    1. Cédrin-Durnerin I, Bständig B, Parneix I, Bied-Damon V, Avril C, Decanter C, Hugues JN. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007;22:109–116.
    1. Guivarc’h-Levêque A, Homer L, Arvis P, Broux PL, Moy L, Priou G, Vialard J, Colleu D, Dewailly D. Programming in vitro fertilization retrievals during working days after a gonadotropin-releasing hormone antagonist protocol with estrogen pretreatment: does the length of exposure to estradiol impact on controlled ovarian hyperstimulation outcomes? Fertil Steril. 2011;96:872–876. doi: 10.1016/j.fertnstert.2011.07.1138.
    1. van Heusden AM, Fauser BC. Residual ovarian activity during oral steroid contraception. Hum Reprod Update. 2002;8:345–358. doi: 10.1093/humupd/8.4.345.
    1. Phillips A, Hahn DW, Klimek S, McGuire JL. A comparison of the potencies and activities of progestogens used in contraceptives. Contracept. 1987;36:181–192. doi: 10.1016/0010-7824(87)90013-8.
    1. Barad DH, Kim A, Kubba H, Weghofer A, Gleicher N. Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? - a pilot study. Reprod Biol Endocrinol. 2013;11:28–33. doi: 10.1186/1477-7827-11-28.
    1. Barmat LI, Chantilis SJ, Hurst BS, Dickey RP. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril. 2005;83:321–330. doi: 10.1016/j.fertnstert.2004.06.076.
    1. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem A, Devroey P. Prolongation of follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle- stimulating hormone and gonadotrophin-releasing hormone antagonists. Fertil Steril. 2004;82:102–107.
    1. Tremellen KP, Lane M. Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes. Hum Reprod. 2010;25:1219–1224. doi: 10.1093/humrep/deq059.
    1. Orvieto R, Kruchkovich J, Rabinson J, Zohav E, Anteby EY, Meltcer S. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs. Fertil Steril. 2008;90:228–230. doi: 10.1016/j.fertnstert.2007.06.022.
    1. Orvieto R. The ultrashort flare GnRH-agonist/GnRH-antagonist protocol enables cycle programming and may overcome the "detrimental effect" of the oral contraceptive. Fertil Steril. 2012;98:e17–18. doi: 10.1016/j.fertnstert.2012.06.053.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe